PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials - Takeaways - MDSpire

PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials

  • By

  • Zhilong Huang

  • Wenwen Li

  • Minghong Li

  • Yifu Huang

  • Yongjiang Lu

  • Jiahang Hu

  • June 1, 2026

  • 0 min

Share

  • 1

    The study evaluates the efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy for advanced or metastatic endometrial cancer.

  • 2

    Ten randomized controlled trials with 4,052 patients were included, showing significant improvements in overall and progression-free survival.

  • 3

    Median overall survival was 43.7 months with PD-1/PD-L1 inhibitors compared to 29.1 months with chemotherapy alone.

  • 4

    The most common treatment-related adverse events included fatigue, alopecia, nausea, and anemia.

  • 5

    The combination therapy showed significant benefits in dMMR patients, with no overall survival benefit observed in pMMR patients.

Original Source(s)

PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials

  • by Zhilong Huang, Wenwen Li, Minghong Li, Yifu Huang, Yongjiang Lu, Jiahang Hu

  • June 1, 2026

Related Content

Existing and emerging strategies for fertility preservation in female patients with leukemia

Multidimensional exposure architecture shapes vaping-associated transcriptomic dysregulation in oral epithelium

Exercise interventions for depressive symptoms in adults with lung and digestive cancer: a meta-analysis of randomized controlled trials